anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The temporomandibular joint (TMJ) is a complex joint that facilitates mandibular movements during speech, chewing, and swallowing activities. The Axis I evaluation of the DC/TMD focuses on assessing physical diagnoses related to TMDs. It includes an assessment of pain and functional limitations, such as jaw opening range, joint sounds, and joint tenderness. The Axis II evaluation of the DC/TMD provides information on the patient's psychological status and quality of life. This Systematic Review with Meta-Analysis aimed to evaluate the accuracy of Temporomandibular Disorders diagnosis considered through the Diagnostic Criteria for Temporomandibular Disorder (DC/TDM) axis II compared to the Axis I evaluations.
METHODS: A search was made in PubMed, Web of Science and Lilacs for articles published from the inception until 20 January 2023. We applied the Population, Exposure, Comparator, and Outcomes (PECO) model [1] to assess document eligibility. Only studies that evaluated patients by DC/TMD Axis I and Axis II were considered. Review Manager version 5.2.8 (Cochrane Collaboration) was used for the pooled analysis. We measured the odds ratio (OR) between the two groups (Axis I and Axis II).
RESULTS: Fifty-one articles were selected because of the search. Four papers were excluded before the screening: 2 pieces were not in English, and two were reviewed. The remaining 47 articles were selected for the title and abstract screening to evaluate whether they met the PECO criteria. Among these, four papers were established; the overall effect showed that there was no difference in TMD diagnosis between Axis I and Axis II (RR 1.17; 95% CI: 0.80- 1.71; Z:0.82; P = .41), suggesting that there is no difference between Axis I and Axis II.
CONCLUSION: In conclusion, DC/TMD is an effective tool for the diagnosis of TMD. It improves the accuracy of TMD diagnosis, allows for the classification of subtypes, and assesses psychosocial factors that may impact the development or maintenance of TMD symptoms.
PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
The study is a randomized, controlled, open-label, multi-center non-inferiority trial to demonstrate that the interval between internation normalized ration (INR) tests can be extended from the recommended 4 weeks to 12 weeks for patients with stable INRs. PROBE design. Patients receiving warfarin therapy that have exhibited INR stability, defined as no change in maintenance dose for at least 6 months, are potentially eligible for enrolment in the study. The primary outcome is a composite of major bleeding (ISTH criteria) plus objectively verified arterial or venous thromboembolism (excluding superficial thrombophlebitis) plus death related to thromboembolism. Justification: the study is not reflecting a "trade-off" scenario where one regimen is expected to be more effective at the cost of increased harm compared to the other regimen. Conversely, the potential disadvantage of the experimental regimen in this trial is increased variability in INR, which may result in an increased rate of low as well as high INRs and therefore potentially an increase of both types of clinical events.
Systems and methods to code medical records using weighted belief networks are provided. Medical records are received, and may be subjected to pre-processing which includes deduplication of records, indexing the records, meta-tagging the records, and annotating the records. An entity extractor then generates entity dictionaries from public sources. A network creator generates a belief network based on medical relationships. An annotation aligner receives normalized annotations of historical medical records, and a network weighter assigns probability values to the belief network using the normalized annotations to generate a weighted belief network. A health care code classifier utilizes the weighted belief network to classify the medical records by comparing entities within the medical records.
One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will be prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.
Full-thickness high-grade squamous intraepithelial lesions (HSIL) are precursors of invasive cervical squamous cell carcinoma (SCC). The World Health Organization and Lower Anogenital Squamous Terminology Standardization Project for human papilloma virus (HPV)-associated lesions divide full-thickness HSIL of the cervix into thin HSIL with thickness of 1 to 9 cell layers and the typical full-thickness HSIL of >10 cell layers. Although HPV oncogene transcripts and p16ink4a overexpression, as markers of transforming HPV infection, are detectable in thin HSIL, the biological significance of thin HSIL in cervical carcinogenesis remains poorly understood. To further characterize thin HSIL, we performed a comparative study of chromosomal copy number variations (CNV), an analysis of dysregulated genes present in the segments with CNV, and a generalized genetic complexity calculation for 31 thin HSIL, 31 thick HSIL, 24 microinvasive SCC (pT1a SCC), and 22 highly invasive SCC samples. Thin HSIL share various CNV and specific dysregulated gene pathways with thick HSIL and invasive SCC. Thin HSIL exhibited an average CNV of 11.6% compared with 14.1% for thick HSIL, 15.5% for pT1a SCC, and 26.6% for highly invasive SCC. The CNV included gains at 1q and 3q (40% and 43%, respectively), partial loss of 3p, and loss of chromosomes 11 (18%), 16 (50%), 20 (35%), and 22 (40%). Pathways affected solely in thin HSIL were those enhancing immune evasion and primarily involved the (interleukin) IL6, IL21, and IL23 genes. ILs are transiently upregulated in response to infection and play a crucial role in mounting antitumor T-cell activity. Deregulation reflects an attempt by the HPV to evade the initial immune response of the host. The primary pathways shared by thick HSIL and invasive SCC were interactions between lymphoid and nonlymphoid cells, NOTCH2 signaling, tight junction interactions (primarily of the claudin family), and FGR2 alternative splicing. Our results show that thin HSIL carry similar genetic changes as thick HSIL and SCC, indicating that thin HSIL are true precursor lesions that can progress to thick HSIL and SCC.
Roweepra (levetiracetam USP) is given orally with or without food. The levetiracetam dosing regimen depends on the indication, age group, dosage form (tablets), and renal function.

Prescribe the oral solution for pediatric patients with body weight ≤ 20 kg. Prescribe the oral solution or tablets for pediatric patients with body weight above 20 kg.

When using the oral solution in pediatric patients, dosing is weight-based (mg per kg) using a calibrated measuring device (not a household teaspoon or tablespoon). 

Roweepra (levetiracetam USP) tablets should be swallowed whole. Roweepra (levetiracetam USP) tablets should not be chewed or crushed.
INTRODUCTION: This study aims to assess the effect of enlarged perivascular spaces (EPVS) in patients using the methods of scale score and 3D volume quantification and to determine whether EPVS progression is related to the occurrence of silent lacunar infarction (SLI).
METHOD: Three hundred sixty-seven elderly patients with EPVS were screened by MRI on the day of admission and 2 years later; 295 patients were included in the final study, among which 136 patients had EPVS with SLI (EL); and 159 patients had EPVS without SLI (EOL). Both scale score and 3D volume quantification method were used to evaluate EPVS. The 295 patients were divided into three groups based on EPVS progression state: Group 1 (no progression), Group 2 (0-50% EPVS progression), and Group 3 (≥ 50% EPVS progression). Multiple logistic regression analysis was used to analyze the risk of occurrence of SLI.
RESULTS: The EPVS scores and ΔEPVS scores were not significantly different between the EL and EOL groups (p > 0.05). EPVS volumes and their progression were significantly higher in EL compared with EOL (p < 0.001). The incidence of SLI was increased in Groups 2 and 3 compared with those in Group 1, and the trend test showed statistically significant (p = 0.032). Multiple logistic regression analysis showed that the risk of occurrence of SLI was significantly increased in Group 2 (OR 2.24; p = 0.024) and Group 3 (OR 3.31; p = 0.037) versus that in Group 1.
CONCLUSION: 3D volume quantification allows for a more sensitive assessment of EPVS changes, and the progression of EPVS volume may contribute to the occurrence of SLI.
With the promise of a potentially single-dose curative regimen, CAR-T cell therapies have brought a paradigm shift in the treatment and management of hematological malignancies with 6 approved products in the USA. However, there are no approved CAR-T cell therapies for solid tumors. Herein, we report the clinical pharmacology profile of AMG 119, the first CAR-T cell therapy targeting delta-like ligand 3 (DLL3), in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC). AMG 119 demonstrated robust cellular expansion with long-lasting cell persistence and a favorable exposure-response relationship. AMG 119 has been demonstrated to be clinically safe and well tolerated at the doses tested, with no dose-limiting toxicities (DLTs) reported. This is the first publication of the clinical pharmacology profile of a CAR-T cell therapy in SCLC, with encouraging cellular kinetics data supporting the potential for CAR-T cell therapy in solid tumor space.
BACKGROUND: The obesity epidemic has led to an increase in the proportion of patients with chronic liver disease due to metabolic associated steatosic liver disease and in the prevalence of obesity in patients with cirrhosis. Metabolic and bariatric surgery (MBS) has been proven to determine weight loss, obesity-related medical problems remission, and liver steatosis, inflammation, and fibrosis improvement. However, cirrhosis and portal hypertension are well-known risk factors for increased morbidity and mortality after surgery. The aim of this study is to evaluate the safety of MBS in patients with compensated advanced chronic liver disease (cALCD) and clinically significant portal hypertension (CSPH).
MATERIAL AND METHODS: This is an international, multicentric, retrospective study on 63 individuals affected by obesity with cALCD and CSPH who underwent MBS in tertiary referral centers with experts hepatobiliary surgeons between January 2010 and October 2022. The primary endpoint was postoperative mortality at 90 days. The secondary endpoints included postoperative weight loss at last follow-up and postoperative complication rate. In addition, the authors performed subgroup analyses of Child-Pugh (A vs. B) score, MELD (≤9 vs. >9) score, and type of surgery.
RESULTS: One patient (1.6%) experienced gastric leakage and mortality. There were three (5%) reported cases of portal vein thrombosis, two (3%) postoperative acute renal failure, and one (1.6%) postoperative encephalopathy. Child-Pugh score A resulted to be a protective factor for intraoperative bleeding requiring transfusion at univariate analysis (OR: 0.73, 95% CI: 0.55-0.97, P =0.046) but not at multivariate analysis. MELD>9 score and the type of surgery did not result to be a risk factor for any postoperative complication.
CONCLUSION: MBS is safe in patients with cALCD and CSPH performed in tertiary bariatric referral centers with hepatobiliary expert surgeons. Larger, prospective studies with longer follow-up periods are needed to confirm these results.
PURPOSE:The titled remedy, containing a saccharide and protein consisting essentially of xylose obtained from a mycelial culture of a fungus belonging to the basidiomycetes, e.g. SHIITAKE mushroom, cultivated in a solid culture medium rich in the xylose component. CONSTITUTION:A remedy for dermatosis consisting of a saccharide and protein consisting essentially of xylose in a mycelial culture of a fungus belonging to the basidiomycetes, e.g. SHIITAKE mushroom, cultivated in a solid culture medium, e.g. bagasse or rice bran, rich in the xylose component as a main component. The causes of the dermatosis can be roughly divided into diseases due to the immunity disorder and diseases due to viruses or bacteria. The remedy exhibits improved remedial effect on either one thereof. This is considered due to the enhancement of the cellular activity by the administration or application thereof, and the strengthening of the antibody against the antigen, i.e. the enhancement of the immunological activity.
The apparatus and method is operable to receive data 24 relating to an event, input the received data into an artificial neural network which provides a learning model 14, receive first output data from the learning model representing a predicted duration of a task 16 resulting from the event, receive second output data from the learning model representing the predicted resources required at the end of the predicted task duration 18, and allocate the predicted resources available at or near the end of the predicted duration of the task 20. The apparatus may additionally be operable to search databases 22 for the predicted resources available at or near the end of the predicted duration, and reserve the predicted resources at the databases. The event may be a hospital admissions event, where the data is captured from a doctor. The predicted task duration may be likely duration of hospitalisation. The resources may be medical or care resources. The invention may also reserve processing or memory resources in a computer or ensure resources are available for delivery at a later time. The invention enables resources to be allocated for delivery or performance at, or close to, the appropriate time in the future.
Participants with chronic pancreatitis scheduled for endoscopic therapy will undergo baseline assessments including EEG, quantitative sensory testing, and psychosocial questionnaires. Follow-up questionnaires will be completed at approximately 3, 6, 12 and 18 months post-procedure.
Preparation

Measure the dose using either a scale accurate to at least 0.1 gram, or a graduated teaspoon, accurate to the fraction of the dose to be administered.

Once the measured dose has been removed from the XURIDEN packet, discard the unused portion of granules. Do not use any granules left in the open packet.

Administration with Food

  1. Place 3 to 4 ounces of applesauce, pudding or yogurt in a small clean container.
  2. Mix the measured amount of granules in the applesauce, pudding or yogurt
  3. Swallow applesauce/pudding/yogurt immediately. Do not chew the granules. Do not save the applesauce/pudding/yogurt for later use.
  4. Drink at least 4 ounces of water.



Administration in Milk or Infant Formula

XURIDEN can be mixed with milk or infant formula instead of the soft foods described above for patients receiving up to 3/4 teaspoon (2 grams) of XURIDEN. After weighing the dose of XURIDEN:

  1. Pour 5 mL of milk or infant formula into a 30 mL medicine cup.
  2. Insert the tip of the oral syringe into the medicine cup and draw up 5 mL of milk/infant formula into the syringe.
  3. Hold the syringe with the tip pointing upward. Pull down on the plunger until the plunger reaches 10 mL. This will add air to the syringe.
  4. Place the cap over the tip of the syringe. Then invert the syringe so the syringe tip is pointing down, and remove the plunger.
  5. Pour the measured amount of XURIDEN granules into the syringe barrel and reinsert the syringe plunger. Do not push up on the plunger.
  6. Gently swirl the syringe to mix the XURIDEN granules with the liquid.
  7. Turn the syringe so the syringe tip is pointing up. Then remove the syringe cap and push up on the plunger until the plunger reaches the 5 mL mark. This will remove air from the syringe.
  8. Place the tip of the syringe in the patient's mouth between the cheek and gum at the back of the mouth. Gently push the plunger all the way down.
  9. Refill the syringe with another 5 mL of milk/infant formula.
  10. Gently swirl the syringe to rinse any remaining XURIDEN granules from the syringe barrel.
  11. Place the tip of the syringe in the patient's mouth between the cheek and gum at the back of the mouth. Gently push the plunger all the way down.
  12. Follow with a bottle of milk or infant formula, if desired.
PURPOSE: A composition containing Punica granatum extract and red ginseng extract for preventing or treating diabetes or obesity is provided to suppress glucose absorption and alpha-glucosidase activation. CONSTITUTION: A composition for preventing or treating diabetes or obesity contains Punica granatum and red ginseng extracts. The Punica granatum extrac is isolated flower, peel, seed, fruits of the Punica granatum using extraction solvent. The extraction solvent is water. The Punica granatum extract and red ginseng extract is contained in the ratio of 7:3-3:7. The composition additionally contains Morus alba L. extract, Sasa borealis extract, amino acid, vitamin, mineral, sweetener, or dietary fiber. The composition is food composition or drink.
This research is being done because the standard treatments for prostate cancer that has returned (PSA is elevated) after surgery and/or radiation and progressed on initial hormonal therapy are not curative. Existing treatments, such as the ketoconazole used as part of this study may decrease PSA temporarily, but unfortunately the cancer continues to grow. This experimental drug is designed to seek out all of the prostate cancer cells and to deliver a lethal dose of radiation to the areas of cancer, but not to normal areas. Some of the normal organs (liver, kidney and bone marrow) do receive some radiation dose that is within the acceptable limits.

The experimental drug in this study includes an antibody (abbreviated: mAb) called "J591". It is a protein molecule which can bind to a specific site on a prostate cancer cell. A very energetic radioactive (an unstable atom) metal called 177Lutetium (abbreviated: 177Lu) is attached to the J591 antibody. The fully assembled drug is called "177Lu-J591". The study will assess the potential of the energy given off by the radioactive compound to kill cancer cell. This study may also involve the use of 111Indium (abbreviated 111In). This is also an energetic radioactive particle, but does not generally give off enough energy to kill cancer cells, but allows researchers to take pictures. This radioactive particle is also attached to the J591 antibody (called 111In-J591) and will serve as a placebo (treatment with no active medicine).
PURPOSE:To efficiently express mixed antigenic spherical particles from the resultant transformant, by introducing an extraneous peptide-HBs fused polypeptide expression plasmid into a transformant containing an HBs gene on a chromosomic gene of a yeast. CONSTITUTION:An HBs expression gene is fragmented and a gene (e.g. a gene capable of coding ribosomal gene of yeast) coded on a chromosome of a yeast is linked to both ends thereof. The above-mentioned fragment is used to transform a yeast and create an integration yeast having the HBs gene integrated on the chromosomic gene of the yeast. A plasmid capable of expressing a fused polypeptide having an extraneous polypeptide (e.g. HBpreS1 or HBpreS2) linked to the N-terminal of the HBs polypeptide or partial polypeptide thereof is further introduced and the resultant transformant is cultured to afford mixed antigenic particles consisting of the fused polypeptide having the extraneous polypeptide linked to the N-terminal of the HBs polypeptide and the HBs polypeptide.
PROBLEM TO BE SOLVED: To obtain an antiphlogistic sedative medicine composition excellent in anti-inflammatory effect and analgesic effect, not coloring in yellow, containing piroxicam. SOLUTION: This antiphlogistic sedative medicine composition comprises 0.1-10wt.% of piroxicam of the formula, 85-99.8wt.% of a liquid suspension medium (e.g. isopropyl alcohol) substantially not dissolving piroxicam and 0.1-5wt.% of a fatty acid dextrin as active ingredients. The composition is prepared by thickening a dispersion system in which fine powder of piroxicam is dispersed into the liquid suspension medium with the fatty acid dextrin. Consequently, the composition will not color in yellow. Since the composition is thickened by the fatty acid dextrin, the fine powder of piroxicam is prevented from precipitating and maintained in a stabilized dispersion state. Therefore, the antiphlogistic sedative medicine composition not causing a yellow spot on an applied part, a finger, etc., not staining clothing, etc., even if the composition is attached to the clothing, etc.
The present disclosure relates to the field of medicaments, and particularly to use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for reducing a serum uric acid level and preventing and treating uric acid nephropathy, and belongs to the field of medicaments. In one aspect, the present disclosure provides use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for reducing a serum uric acid level. In another aspect, the present disclosure further provides use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for treating and/or preventing uric acid nephropathy. Animal experiments have confirmed that the Liriodendron chinense (Hemsl.) Sarg. can significantly reduce the serum uric acid level, and relieve degrees of renal tubular dilation, glomerulosclerosis, and renal interstitial fibrosis of hyperuricemic mice. Further research shows that the Liriodendron chinense (Hemsl.) Sarg. plays a role in reducing the serum uric acid level by promoting renal uric acid excretion. The use of the present disclosure can provide a new medicament choice for clinical treatment of hyperuricemia and hyperuricemic nephropathy caused by the hyperuricemia.